Smith D J, Paulson G D
Biosciences Research Laboratory, ARS, USDA, Fargo, ND 58105.
J Anim Sci. 1994 Feb;72(2):404-14. doi: 10.2527/1994.722404x.
Objectives of this study were 1) to measure the effect of oral or i.p. administration of ractopamine HCl on growth and feed utilization in rats, 2) to determine the total absorption of [14C]ractopamine HCl after oral administration, and 3) to determine the disposition of radioactivity and the urinary elimination of unchanged [14C]ractopamine in rats after oral or i.p. administration of [14C]ractopamine. Twenty-seven female Sprague-Dawley rats (164.6 +/- 5.7 g) were randomly assigned to control (CONT), oral (ORAL), and i.p. (IP) treatments. Control and ORAL rats were implanted i.p with sham pumps, and IP rats were implanted i.p. with osmotic pumps primed to deliver 312 micrograms of ractopamine HCl per 24 h. Control and IP rats received no dietary ractopamine, but ORAL rats received 20 mg of ractopamine HCl/kg of diet. The IP rats had greater cumulative net weight gains and ADG on d 2, 6, 8, 10, and 12 than CONT rats. The ADFI was greater for ORAL rats on d 2 and 4 than for CONT rats, and the gain:feed ratio was greater on d 2, 6, 8, 10, and 12 for IP rats than for CONT rats. Net weight gain, ADG, and gain:feed ratio did not differ between ORAL and CONT rats. Absorption of radioactivity administered orally as [14C]ractopamine (2.9 mg) was 87.9% during a 24-h experimental period; biliary, urinary, and fecal excretion of radioactivity was 58.5%, 28.7%, and 1.4% of that administered, respectively. Urine from rats dosed orally with [14C]ractopamine contained 1.9% of the radioactivity as the parent compound, and urine from rats dosed i.p. contained 22.6% of the radioactivity as parent ractopamine. Ractopamine HCl increased weight gain and efficiency of feed utilization when administered i.p. to rats, but not when administered orally. The ineffectiveness of oral ractopamine for stimulating the growth of rats was probably due to extensive presystemic metabolism of ractopamine.
1)测定口服或腹腔注射盐酸莱克多巴胺对大鼠生长及饲料利用率的影响;2)测定口服[14C]盐酸莱克多巴胺后的总吸收量;3)测定口服或腹腔注射[14C]莱克多巴胺后大鼠体内放射性物质的分布及未变化的[14C]莱克多巴胺的尿排泄情况。27只雌性斯普拉格-道利大鼠(体重164.6±5.7克)被随机分为对照组(CONT)、口服组(ORAL)和腹腔注射组(IP)。对照组和口服组大鼠腹腔内植入假泵,腹腔注射组大鼠腹腔内植入渗透泵,设定为每24小时输送312微克盐酸莱克多巴胺。对照组和腹腔注射组大鼠饲料中未添加莱克多巴胺,但口服组大鼠饲料中添加20毫克/千克体重的盐酸莱克多巴胺。腹腔注射组大鼠在第2、6、8、10和12天的累积净增重和平均日增重高于对照组。口服组大鼠在第2天和第4天的日均采食量高于对照组,腹腔注射组大鼠在第2、6、8、10和12天的增重:采食量比值高于对照组。口服组和对照组大鼠的净增重、平均日增重及增重:采食量比值无差异。口服给予[14C]莱克多巴胺(2.9毫克)后,在24小时实验期内放射性物质的吸收量为87.9%;放射性物质的胆汁、尿液和粪便排泄量分别为给药量的58.5%、28.7%和1.4%。口服[14C]莱克多巴胺的大鼠尿液中,以母体化合物形式存在的放射性物质占1.9%,腹腔注射给药的大鼠尿液中,以母体莱克多巴胺形式存在的放射性物质占22.6%。腹腔注射盐酸莱克多巴胺可增加大鼠体重并提高饲料利用率,但口服给药则无此效果。口服莱克多巴胺对大鼠生长无促进作用可能是由于莱克多巴胺在体循环前发生了广泛的代谢。